{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T01:34:50Z","timestamp":1715996090127},"reference-count":66,"publisher":"American Society for Microbiology","issue":"8","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2014,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>A W153L substitution in HIV-1 reverse transcriptase (RT) was recently identified by selection with a novel nucleotide-competing RT inhibitor (NcRTI) termed compound A that is a member of the benzo[4,5]furo[3,2,d]pyrimidin-2-one NcRTI family of drugs. To investigate the impact of W153L, alone or in combination with the clinically relevant RT resistance substitutions K65R (change of Lys to Arg at position 65), M184I, K101E, K103N, E138K, and Y181C, on HIV-1 phenotypic susceptibility, viral replication, and RT enzymatic function, we generated recombinant RT enzymes and viruses containing each of these substitutions or various combinations of them. We found that W153L-containing viruses were impaired in viral replicative capacity and were hypersusceptible to tenofovir (TFV) while retaining susceptibility to most nonnucleoside RT inhibitors. The nucleoside 3TC retained potency against W153L-containing viruses but not when the M184I substitution was also present. W153L was also able to reverse the effects of the K65R substitution on resistance to TFV, and K65R conferred hypersusceptibility to compound A. Biochemical assays demonstrated that W153L alone or in combination with K65R, M184I, K101E, K103N, E138K, and Y181C impaired enzyme processivity and polymerization efficiency but did not diminish RNase H activity, providing mechanistic insights into the low replicative fitness associated with these substitutions. We show that the mechanism of the TFV hypersusceptibility conferred by W153L is mainly due to increased efficiency of TFV-diphosphate incorporation. These results demonstrate that compound A and\/or derivatives thereof have the potential to be important antiretroviral agents that may be combined with tenofovir to achieve synergistic results.<\/jats:p>","DOI":"10.1128\/aac.02729-14","type":"journal-article","created":{"date-parts":[[2014,5,28]],"date-time":"2014-05-28T07:08:08Z","timestamp":1401260888000},"page":"4515-4526","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":2,"title":["Effects of the W153L Substitution in HIV Reverse Transcriptase on Viral Replication and Drug Resistance to Multiple Categories of Reverse Transcriptase Inhibitors"],"prefix":"10.1128","volume":"58","author":[{"given":"Hong-Tao","family":"Xu","sequence":"first","affiliation":[{"name":"McGill University AIDS Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan P.","family":"Colby-Germinario","sequence":"additional","affiliation":[{"name":"McGill University AIDS Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maureen","family":"Oliveira","sequence":"additional","affiliation":[{"name":"McGill University AIDS Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Rajotte","sequence":"additional","affiliation":[{"name":"Department of Biological Sciences, Boehringer Ingelheim (Canada) Ltd., Laval, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Bethell","sequence":"additional","affiliation":[{"name":"Department of Biological Sciences, Boehringer Ingelheim (Canada) Ltd., Laval, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A.","family":"Wainberg","sequence":"additional","affiliation":[{"name":"McGill University AIDS Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada"},{"name":"Department of Medicine, McGill University, Montreal, Quebec, Canada"},{"name":"Department of Microbiology and Immunology, McGill University, Montreal, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a007161"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0b013e328361fabd"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-124-12-199606150-00001"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.277.5322.112"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2009.07.006"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2008.10.071"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200309011-00002"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1004180"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.3390\/v2020606"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2007.12.018"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2007.12.015"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2013.01.007"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00889-06"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00127-06"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M804882200"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2011.05.004"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00113-13"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(17)36678-4"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4690-7-80"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.74.23.10958-10964.2000"},{"key":"e_1_3_2_22_2","first-page":"817","article-title":"Retroviral reverse transcriptase: synthesis, structure, and function","volume":"3","author":"Goff SP","year":"1990","unstructured":"GoffSP. 1990. Retroviral reverse transcriptase: synthesis, structure, and function. J. Acquir. Immune Defic. Syndr. 3:817\u2013831.","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01192-10"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01795-09"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05821-11"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32835d9f6d"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/0076-6879(95)62015-X"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-1033.1990.tb15306.x"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1089\/088922203769232548"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.05584-11"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02904-13"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4690-6-14"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.74.8.3579-3585.2000"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00800-09"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02005-12"},{"key":"e_1_3_2_36_2","first-page":"6","article-title":"Update of the drug resistance mutations in HIV-1: March 2013","volume":"21","author":"Johnson VA","year":"2013","unstructured":"JohnsonVACalvezVGunthardHFParedesRPillayDShaferRWWensingAMRichmanDD. 2013. Update of the drug resistance mutations in HIV-1: March 2013. Top. Antivir. Med. 21:6\u201314.","journal-title":"Top. Antivir. Med."},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01536-13"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1996.tb00777.x"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.70.4.2146-2153.1996"},{"key":"e_1_3_2_40_2","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1177\/135965350100600205","article-title":"Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication","volume":"6","author":"Naeger LK","year":"2001","unstructured":"NaegerLKMargotNAMillerMD. 2001. Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication. Antivir. Ther. 6:115\u2013126.","journal-title":"Antivir. Ther."},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.73.10.8448-8456.1999"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.11.2484"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M710148200"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.153783"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.73.7.5803-5813.1999"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.17.11157"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.74.18.8390-8401.2000"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi002328a"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi9600308"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.2174\/157016208783885065"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2006.01.014"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01545-09"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0609642104"},{"key":"e_1_3_2_54_2","first-page":"22","article-title":"K65R, TAMs and tenofovir","volume":"6","author":"Miller MD","year":"2004","unstructured":"MillerMD. 2004. K65R, TAMs and tenofovir. AIDS Rev. 6:22\u201333.","journal-title":"AIDS Rev."},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00714-06"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3181ea0df8"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e3181af5a00"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4690-10-65"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1128\/CDLI.10.6.979-981.2003"},{"key":"e_1_3_2_60_2","first-page":"S21","article-title":"XV International HIV Drug Resistance Workshop: Basic Principles & Clinical Implications. The in vitro resistance profile of NcRTI is complementary with the resistance profile of tenofovir and zidovudine","volume":"11","author":"Jochmans D","year":"2006","unstructured":"JochmansDVan GimderenMDe BaereIDehertoghPHallenbergerSHertogsK. 2006. XV International HIV Drug Resistance Workshop: Basic Principles & Clinical Implications. The in vitro resistance profile of NcRTI is complementary with the resistance profile of tenofovir and zidovudine. Antivir. Ther. 11(Suppl 1):S21.","journal-title":"Antivir. Ther."},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1177\/095632020701800603"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000189851.21441.f1"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.13.8.933"},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00348-13"},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00271-12"},{"key":"e_1_3_2_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2013.04.043"},{"key":"e_1_3_2_67_2","volume-title":"Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection","author":"WHO","year":"2013","unstructured":"WHO. 2013. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. World Health Organization, Geneva, Switzerland. http:\/\/www.who.int\/hiv\/pub\/guidelines\/arv2013\/en\/. Accessed 10 January 2014."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02729-14","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02729-14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T18:41:35Z","timestamp":1689273695000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02729-14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":66,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["10.1128\/AAC.02729-14"],"URL":"https:\/\/doi.org\/10.1128\/aac.02729-14","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"2014-03-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-05-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-07-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}